Table 4 Wei–Lin–Weissfeld model on WBC recovery including all patients receiving three consolidation cycles

From: Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia

 

HR

95% CI

P-value

HDAC-123a

1.94

1.67–2.24

<0.0001

Pegfilgrastim application

1.58

1.37–1.84

<0.0001

Age (10 years difference)

0.89

0.83–0.95

0.001

ELN risk group according to reference 2 b

 Low

1.06

0.89–1.26

0.51

 Intermediate 2

0.95

0.75–1.22

0.70

 High

1.32

0.95–1.85

0.10

Male gender

1.12

0.96–1.32

0.15

s/t-AML

0.90

0.64–1.24

0.51

  1. Abbreviations: AML, acute myeloid leukemia; CI, confidence interval; ELN, European LeukemiaNet; HDAC, high-dose cytarabine; HR, hazard ratio; s/t-AML, secondary AML after a proceeding myelodysplastic syndrome/treatment-related AML; WBC, white blood count.
  2. aReference group, HDAC-135.
  3. bReference group, intermediate 1.
Back to article page